Chawla, S. P., Van Tine, B. A., Pollack, S., Ganjoo, K. N., Elias, A. D., Riedel, R. F., Attia, S., Choy, E., Okuno, S. H., Agulnik, M., von Mehren, M., Livingston, M. B., Keedy, V. L., Verschraegen, C. F., Philip, T., Bohac, G. C., Yurasov, S., Lu, H. L., Chen, M., Maki, R. G. (May 2019) A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1(+) soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival. In: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO).
| Item Type: | Conference or Workshop Item (Poster) |
|---|---|
| Subjects: | diseases & disorders > cancer > drugs and therapies > chemotherapy diseases & disorders > cancer > cancer types > sarcoma |
| CSHL Authors: | |
| Communities: | CSHL labs > Maki lab |
| Depositing User: | Matthew Dunn |
| Date: | May 2019 |
| Date Deposited: | 18 Oct 2019 18:55 |
| Last Modified: | 18 Oct 2019 19:09 |
| URI: | https://repository.cshl.edu/id/eprint/38615 |
Actions (login required)
 |
Administrator's edit/view item |